Ocular application of chitosan

Expert Opinion on Drug Delivery

Volumn 9, Issue 6, 2012, Pages 701-712

  Başaran, Ebru ^a   Yazan, Yasemin ^a  

^a ANADOLU UNIVERSITY   (Turkey)

Author keywords

Bioavailability; Chitosan; Ocular drug delivery; Safety of chitosan

Indexed keywords

CHITOSAN; CHLORIDE; FLUCONAZOLE; GELLING AGENT; GLUTAMIC ACID; LACTIC ACID; LIPOSOME; TOBRAMYCIN;

BIOCOMPATIBILITY; BIODEGRADABILITY; CELL PROLIFERATION; CELL VIABILITY; CHELATION; CHEMICAL STRUCTURE; CONJUNCTIVA; CONSTIPATION; CORNEA; CYTOTOXICITY; DEACETYLATION; DEPOLYMERIZATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; EMULSION; FLOW KINETICS; GLASS TRANSITION TEMPERATURE; HUMAN; HYDROGEN BOND; MOLECULAR WEIGHT; NAUSEA; OCULAR DRUG DELIVERY; PH; PHYSICAL CHEMISTRY; REVIEW; SAFETY; SYNTHESIS; VISCOSITY;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG DELIVERY SYSTEMS; EYE DISEASES; GELS; HUMANS; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84862107711     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.681775     Document Type: Review

References (80)

1. Toit L, Pillay V, Choonara YE, et al. Ocular drug delivery -a look towards nanobioadhesives. Expert Opin Drug Deliv 2011;8(1):71-94
2. Cao F, Wanga Y, Ping Q, et al. Zn - Al - NO3-layered double hydroxides with intercalated diclofenac for ocular delivery. Int J Pharm 2011;404:250-6
3. Araujo J, Gonzalez E, Egea MA, et al. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomed Nanotechnol 2009;5:394-401
4. Fuente M, Ravina M, Paolicelli P, et al. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 2010;62:100-17
5. Gratieri T, Gelfuso GM, Freitas O, et al. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Eur JPharm Biopharm 2011;79:320-7
6. Kikuchi T, Suzuki M, Kusai A, et al. Synergistic effect of EDTA and boric acid on corneal penetration of CS-088.Int J Pharm 2005;290:83-9 (Pubitemid 40139047)
7. Shen J, Wang Y, Ping Q, et al. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 2009;137:217-23
8. Granero G, Longhi MR. Promising complexes of acetazolamide for topical ocular administration. Expert Opin Drug Deliv 2010;7(8):943-53
9. Lee TWY, Robinson JR. Ocular penetration enhancers. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. Marcel Dekker, Inc.; USA: 2003. p. 281-309
10. Li N, Zhuang C, Wang M, et al. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 2009;379:131-8
11. Yuan X, Li H, Yuan Y. Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr Polym 2006;65:337-45 (Pubitemid 44160627)
12. Wang S, Zhang J, Jiang T, et al. Protective effect of Coenzyme Q10 against oxidative damage in human lens epithelial cells by novel ocular drug carriers. Int J Pharm 2011;403:219-29
13. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005;57:1595-639 (Pubitemid 41443472)
14. Felt O, Furrer P, Mayer JM, et al. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm 1999;180:185-93 (Pubitemid 29238202)
15. Rupenthal ID, Green CR, Alany RG. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterization and in vitro release. Int J Pharm 2011;411:69-77
16. Santvliet LV, Ludwig A. The influence of penetration enhancers on the volume instilled of eye drops. Eur JPharm Biopharm 1998;45:189-98 (Pubitemid 28167746)
17. Lopes LB, Collerr JH, Vitoria M, et al. Topical delivery of cyclosporin A: an in vitro study using monoolein as apenetration enhancer. Eur JPharm Biopharm 2005;60:25-30 (Pubitemid 40545857)
18. Gratieri T, Gelfuso GM, Rocha EM, et al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur JPharm Biopharm 2010;75:186-93
19. Johnston TP, Dias CS, Mitra AK. Mucoadhesive polymers in ophthalmic drug delivery. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. Marcel Dekker, Inc.; USA: 2003. p. 409-35
20. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003;255:13-32 (Pubitemid 36369587)
21. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001;224:159-68 (Pubitemid 32706495)
22. Basaran E, Demirel M, S?rmagul B, et al. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010;27(1):37-47
23. Luo Q, Zhao J, Zhang X, et al. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011;403:185-91
24. Mahmoud AA, El-Feky GS, Kamel R, et al. Chitosan/ sulfobutylether - cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011;413:229-36
25. Hagigit T, Abdulrazik M, Orucov F, et al. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J Control Release 2010;145:297-305
26. Pignatello R, Ferro M, De Guidi G, et al. 2Preparation, characterisation and photosensitivity studies of solid dispersions of diflunisal and Eudragit RS100® and RL100®.. Int J Pharm 2001;218:27-42 (Pubitemid 32406154)
27. Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002;16:53-61 (Pubitemid 34756782)
28. Basaran E, Demirel M, S?rmagul B, et al. Polymeric cyclosporine-A nanoparticles for ocular application. J Biomed Nanotechnol 2011;7:714-23
29. Meng J, Sturgis TF, Youan BBC. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci 2011;44:57-67
30. Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Chitosan. In: Rowe RC, Sheskey PJ, Quinn ME, editors, Pharmaceutical Excipients, RPS Publishing; USA: 2009. p. 159-61
31. Yenilmez E, Basaran E, Yazan Y. Release characteristics of vitamin E incorporated chitosan microspheres and in vitro-in vivo evaluation for topical application. Carbohydr Polym 2011;84:807-11
32. Gong K, Darr JA, Rehman IU. Supercritical fluid assisted impregnation of indomethacin into chitosan thermosets for controlled release applications. Int J Pharm 2006;315:93-8 (Pubitemid 43674107)
33. Gibson M. Ophthalmic dosage forms. In: Gibson M, editor. Pharmaceutical Preformulation and Formulation. CRC Press LLC; Florida-USA: 2004. p. 461-91
34. Hosoya K, Lee VHL, Kim K-J. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur JPharm Biopharm 2005;60:227-40 (Pubitemid 40804563)
35. Layers of cornea by Lutz Slomianka. Available from: http://www.lab.anhb. uwa.edu.au/mb140/corepages/eye/eye.htm[Last accessed 7 February 2012]
36. Jones D. Ocular, nasal and otic dosage forms. In: Jones D, editor. Pharmaceutics - Dosage Form and Design. RPS Publishing; USA: 2008. p. 135-56
37. Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm 2008;348:175-8 (Pubitemid 350266247)
38. Chastain JE. Ophthalmic drugs. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. Marcel Dekker, Inc.; USA: 2003. p. 59-107
39. Tamilvanan S, Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm 2004;58:357-68 (Pubitemid 39037241)
40. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release 2003;89:151-65 (Pubitemid 36507012)
41. Guibal E. Heterogeneous catalysis on chitosan-based materials: a review. Prog Polym Sci 2005;30:71-109 (Pubitemid 40225755)
42. Agnihotri SA, Mallikarjuna NN, Aminabhavi TA. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release 2004;100:5-28 (Pubitemid 39445982)
43. Baldrick P. The safety of chitosan as apharmaceutical excipient. Regul Toxicol Pharmacol 2010;56:290-9
44. Wilson B, Samanta MK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomed Nanotechnol 2010;6:144-52
45. Casettari L, Vllasaliu D, Castagnino E, et al. PEGylated chitosan derivatives: Synthesis, characterizations and pharmaceutical applications. Prog Polym Sci 2011; doi:10.1016/j.progpolymsci.2011.10.001
46. Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. PSTT 1998;1(6):246-53 (Pubitemid 28439296)
47. Hu Y-L, Qi W, Han F, et al. Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model. Int J Nanomed 2011;6:3351-9
48. Calvo P, Vila-Jato JL, Alonso M. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm 1997;153:41-50 (Pubitemid 27283332)
49. De Campos AM, Sanchez A, Gref R, et al. The effect of a PEG versus achitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003;20:73-81 (Pubitemid 37103234)
50. Nagarwal RC, Kant S, Maiti P, et al. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 2009;136:2-13
51. Wang L-Y, Ma G-H, Su Z-G, et al. Preparation of uniform sized chitosan microspheres by membrane emulsification technique and application as a carrier of protein drug. J Control Release 2005;106:62-75 (Pubitemid 41140082)
52. FDA GRAS Claim Notification ofChitosan. Available from: http://www.accessdata.fda.gov/scripts/fcn/gras-notices/grn000073.pdf[Last accessed 6 February 2012]
53. FDA Chitosan GRAS Notice. Availablefrom: http://www.accessdata.fda.gov/ scripts/fcn/gras-notices/GRN000397.pdf[Last accessed 6 February 2012]
54. Asada M, Takahashi H, Okamoto H, et al. Theophylline particle design using chitosan by the spray drying. Int J Pharm 2004;270:167-74 (Pubitemid 38077097)
55. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010;62:3-11
56. Yoksan R, Chirachanchai S. Amphiphilic chitosan nanosphere: studies on formation, toxicity, and guest molecule incorporation. Bioorgan Med Chem 2008;16:2687-96 (Pubitemid 351380917)
57. Omara EA, Aly HF, Nada SA. Chitosan induced hepato-nephrotoxicity in mice with special reference to gender effect in glycolytic enzymes activities. Regul Toxicol Pharmacol 2012;62:29-40
58. Loh JW, Yeoh G, Saunders M, et al. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. Toxicol Appl Pharmacol 2010;249:148-57
59. Prego C, Torres D, Fernandez-Megia E, et al. Chitosan - PEG nanocapsules as new carriers for oral peptide delivery Effect of chitosan pegylation degree. J Control Release 2006;111:299-308
60. Hu F-Q, Meng P, Dai Y-Q, et al. PEGylated chitosan-based polymer micelle as an intracellular delivery carrier for anti-tumor targeting therapy. Eur JPharm Biopharm 2008;70:749-57
61. Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol 2011;670:372-83
62. Di Colo G, Zambito Y, Burgalassi S, et al. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int J Pharm 2004;273:37-44 (Pubitemid 38317038)
63. Li XY, Kong XY, Wang XH, et al. Gel - sol - gel thermo-gelation behavior study of chitosan - inorganic phosphate solutions. Eur J Pharm Biopharm 2010;75:388-92
64. Ur-Rehman T, Tavelin S, Grobner G. Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int J Pharm 2011;409:19-29
65. Shen J, Deng Y, Jin X, et al. Thiolated nanostructured lipid carriers as apotential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm 2010;402:248-53
66. Yuan X-B, Yuan Y-B, Jiang W, et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 2008;349:241-8
67. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan - sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008;68:513-25 (Pubitemid 351318222)
68. Di Colo G, Zambito Y, Burgalassi S, et al. Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly (ethylene oxide). Int J Pharm 2002;248:115-22 (Pubitemid 35341415)
69. Zambito Y, Di Colo G. Thiolated quaternary ammonium-chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone. Eur J Pharm Biopharm 2010;75:194-9
70. Chenite A, Chaput C, Wang D, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 2000;21:2155-61 (Pubitemid 30612386)
71. Wu J, Su Z-G, Ma G-H. A thermo-and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate. Int J Pharm 2006;315:1-11 (Pubitemid 43674112)
72. Berger J, Reist M, Mayer JM, et al. Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm 2004;57:19-34 (Pubitemid 38058801)
73. Berger J, Reist M, Mayer JM, et al. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm 2004;57:35-52 (Pubitemid 38058802)
74. Wu H, Liu Z, Peng J, et al. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int J Pharm 2011;410:31-40
75. Zhang J, Wang S. Topical use of Coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. Int J Pharm 2009;372:66-75
76. Diebold Y, Jarrin M, Saez V, et al. Ocular drug delivery by liposome - chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007;28:1553-64 (Pubitemid 46027250)
77. Jumaa M, Furkert FH, Muller BW. A new lipid emulsion formulation with high antimicrobial efficacy using chitosan. Eur J Pharm Biopharm 2002;53:115-23 (Pubitemid 34037003)
78. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84
79. Li X, Nie S, Kong J, et al. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008;363:177-82
80. Rodrigues LB, Leite HF, Yoshida MI, et al. In vitro release and characterization of chitosan films as dexamethasone carrier. Int J Pharm 2009;368:1-6 Available from: http://www.lab.anhb.uwa.edu.au/mb140/corepages/eye/ eye.htm